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A 26-year-old man was referred to our tertiary cardiovascular centre due to noctur-
nal agonal respiration and syncope that was occurring with a frequency of four to ﬁve
episodes/year. The electrocardiogram (ECG) showed type I Brugada pattern with J waves
seen on lateral leads (Fig. 1). Although the patient’s previous ECG records were all compat-
ible with Brugada pattern, a speciﬁc diagnosis was not made and a speciﬁc treatment was
not given. The patient’s family history was negative for sudden cardiac death. Echocardiog-
raphy was free of any sign of structural heart disease, with normal left ventricular function.
Cardiac magnetic resonance showed normal right ventricular anatomy and function. The
patient was implanted an implantable cardioverter-deﬁbrillator (ICD) for primary prophy-
laxis. A week after discharge, the patient was readmitted to the emergency department
due to frequent ICD shocks. Device interrogation revealed four episodes of polymorphic
ventricular tachycardia that initiated with premature ventricular contractions of different
coupling intervals (Fig. 2), which were appropriately cardioverted to sinus rhythm dur-
ing the previous week. Owing to frequent ICD shocks, we planned to give quinidine for
arrhythmia control; however, as quinidine was not available in our country, we admin-
istered cilostazol at a dose of 100mg twice daily. On the second day of cilostazol, theCilostazole ;
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patient’s ECG converted from type I to type III Brugada pattern with disappearance of J
waves and an increase of 20 beats/min in resting heart rate (Fig. 3). The patient is cur-
rently being followed on cilostazol, free of symptoms and ICD discharge for 10 months;
follow-up ECGs were all compatible with type III Brugada pattern.
Abbreviations: ECG, electrocardiogram; ICD, implantable cardioverter-deﬁbrillator.
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Figure 1. Type I Brugada pattern in a patient with recurrent syncope. Note coved ST-segment elevation≥ 2mm (0.2mV) followed by
negative T waves in right precordial leads. Also, the electrocardiogram shows epsilon (arrowhead) waves, which are very rare for Brugada
syndrome.
Figure 2. Cardioversion of a polymorphic ventricular tachycardia to sinus rhythm with an appropriate implantable cardioverter-
deﬁbrillator shock.Figure 3. Conversion of type I Brugada pattern to type III under cilostazol treatment.
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Although spontaneous conversion of type I to type III
attern (which is considered to be a more benign elec-
rocardiographic variant) is frequent in Brugada syndrome,
e believe that it was due to the drug cilostazol, which
s a phosphodiesterase inhibitor. An increase in calcium
urrent (I-Ca) due to elevation of intracellular cyclic adeno-
ine monophosphate via inhibition of phosphodiesterase
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ctivity might be the mechanism of its antiarrhythmic
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